Simultaneous assay of urine sepiapterin and creatinine in patients with sepiapterin reductase deficiency
Simultaneous assay of urine sepiapterin and creatinine in patients with sepiapterin reductase deficiency
复制标题
墨蝶呤还原酶缺乏症患者尿液墨蝶呤和肌酐的同步测定
DOI:
10.1016/j.cca.2022.07.016
复制
发表时间:
2022
期刊:
影响因子:
5
通讯作者:
Kobayashi K
中科院分区:
文献类型:
--
作者:
Hyodo Y;Akiyama T;Fukuyama T;Mimaki M;Watanabe K;Kumagai T;Kobayashi K
ObjectivesSepiapterin reductase deficiency (SRD) causes central nervous system symptoms due to dopamine and serotonin depletion because sepiapterin reductase plays an important role in tetrahydrobiopterin biosynthesis. SRD cannot be detected by newborn screening because of the absent hyperphenylalaninemia. To diagnose SRD biochemically, confirmation of reduced monoamine metabolites and elevated sepiapterin in the cerebrospinal fluid (CSF) has been considered necessary, because a past study showed no elevation of urine sepiapterin. Recently, however, the elevation of urine sepiapterin in SRD was reported.MethodsWe developed a fast method to measure sepiapterin and creatinine simultaneously using high-performance liquid chromatography with fluorescence and ultraviolet detection. Urine sepiapterin and creatinine were measured in three SRD patients, two SRD carriers, four SRD siblings, and 103 non-SRD patients.ResultsIn the three SRD cases, concentrations of urine sepiapterin were 1086, 914, and 575 µmol/mol creatinine (upper limit: 101.7 µmol/mol creatinine), and were markedly higher than those in other groups. CSF sepiapterin concentration was also measured in one SRD case and it was 4.1 nmol/L (upper limit: 0.5 nmol/L).ConclusionsThe simultaneous determination of urine sepiapterin and creatinine appears helpful for the diagnosis of SRD. This assay system can also be used to measure sepiapterin in the CSF.